← Back to guidelines
Oncology4 papers

Nevoid melanoma

Last edited: 4/15/2026

Overview

Nevoid melanoma brain metastases represent a challenging clinical scenario requiring multidisciplinary management, often involving radiation therapy to control local disease and systemic treatments to improve survival. 12

Diagnosis

  • Imaging: MRI or CT scans for detection and staging of brain metastases.
  • Histopathological confirmation: Biopsy to confirm melanoma origin.
  • Grading: Not explicitly detailed in provided abstracts; typically based on size, number of metastases, and extracranial disease status.
  • Management

  • First-line treatments:
  • - Radiation Therapy: - Whole Brain Radiation Therapy (WBRT): Median survival post-diagnosis of brain metastasis ~3.5 months. - Stereotactic Radiosurgery (SRS): Median survival post-diagnosis of brain metastasis ~7.5 months. 1 - Immunotherapy: Often used in conjunction with radiation therapy to enhance survival outcomes. 2
  • Adjunctive treatments:
  • - Combination of Stereotactic Radiotherapy (SRT) with immunotherapy shows potential survival benefits but requires individualized assessment due to low-quality evidence. 2

    Special Populations

  • No specific details provided regarding management in pregnancy, pediatrics, elderly, or patients with comorbidities based on the given abstracts.
  • Key Recommendations

  • Consider stereotactic radiosurgery (SRS) over whole brain radiation therapy (WBRT) for improved survival in patients with melanoma brain metastases due to longer median survival times observed. (Evidence: Moderate 1)
  • Evaluate the combination of stereotactic radiotherapy (SRT) with immunotherapy on an individual basis, considering potential survival advantages and low rates of ≥G3 late toxicity, acknowledging the very low quality of evidence supporting this approach. (Evidence: Weak 2)
  • Multidisciplinary team discussion is essential for treatment planning in melanoma brain metastases, especially when considering combination therapies like SRT plus immunotherapy. (Evidence: Expert opinion)
  • References

    1 Thompson JF, Williams GJ, Hong AM. Radiation therapy for melanoma brain metastases: a systematic review. Radiology and oncology 2022. link 2 Lancellotta V, Del Regno L, Di Stefani A, Fionda B, Marazzi F, Rossi E et al.. The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. La Radiologia medica 2022. link

    Original source

    1. [1]
      Radiation therapy for melanoma brain metastases: a systematic review.Thompson JF, Williams GJ, Hong AM Radiology and oncology (2022)
    2. [2]
      The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review.Lancellotta V, Del Regno L, Di Stefani A, Fionda B, Marazzi F, Rossi E et al. La Radiologia medica (2022)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG